GlassScriptPhysician profile
Loretta C Grimm
NPI 1558321844
$3,956.51
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $807 · 2022: $1,543 · 2023: $1,390 · 2024: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,606.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $708.16 | 2021-2024 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $664.99 | 2021-2024 | Ozempic, Rybelsus, Tresiba |
| Abbott Laboratories | $511.28 | 2021-2024 | Freestyle Libre 3 |
| Amgen INC. | $417.96 | 2021-2024 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $228.85 | 2021-2023 | Farxiga, Lokelma |
| Sanofi-Aventis U.S. LLC | $206.19 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $168.97 | 2022-2024 | |
| Abbvie INC. | $144.17 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.82 | 2021-2023 | Jardiance |
| Mannkind Corporation | $94.42 | 2022-2023 | Afrezza |
| Insulet Corporation | $88.02 | 2021-2024 | Omnipod |
| Ibsa Pharma INC. | $82.43 | 2021 | |
| Radius Health, INC. | $77.63 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $74.85 | 2022 | |
| Corcept Therapeutics | $67.24 | 2022-2023 | Korlym |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $64.85 | 2022-2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $45.44 | 2021-2023 | Steglatro |
| Novartis Pharmaceuticals Corporation | $36.97 | 2022 | |
| Recordati_rare_diseases_inc. | $27.97 | 2023 | Isturisa, Signifor Lar |
| Becton, Dickinson and Company | $27.10 | 2021-2022 | |
| Rgh Enterprises LLC | $19.34 | 2024 | |
| Opko Pharmaceuticals, LLC | $18.29 | 2022 | |
| Pfizer INC. | $17.39 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $15.30 | 2023 | Inpefa |
| Averitas Pharma INC. | $15.15 | 2024 | Qutenza |
| Amryt Pharma Holdings LTD | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loretta Grimm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.